SCHEMBL5507155

SCHEMBL5507155

CC(C)(C)OC(=O)N1CCC(Oc2ccnc3ccc(C=O)cc23)CC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.54
PDE4B Q07343 3/20 0.47
PDE4D Q08499 3/20 0.47
PDE4A P27815 2/20 0.47
PDE4C Q08493 2/20 0.47
PIK3CD O00329 3/20 0.46
PIK3CA P42336 3/20 0.46
PIK3CB P42338 3/20 0.46
PIK3CG P48736 3/20 0.46
GPR119 Q8TDV5 9/20 0.44
CHEK2 O96017 1/20 0.43
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23360277 0.87 IDO1 (0.56) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL29862644 0.87 IDO1 (0.56) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL20074469 0.86 IDO1 (0.55) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL5499611 0.86 IDO1 (0.55) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL17729205 0.86 IDO1 (0.69) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL29862793 0.84 IDO1 (0.56) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL23360106 0.84 IDO1 (0.56) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL23707520 0.83 IDO1 (0.52) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL5504950 0.82 IDO1 (0.46) IDO1PDE4BPDE4DPDE4APDE4C
SCHEMBL14437316 0.82 GPR119 (0.48) IDO1PDE4BPDE4DPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253285-B2 Thiazolinone 4-monosubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
US-7253285-B2 Thiazolinone 4-monosubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
US-7253285-B2 Thiazolinone 4-monosubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
EP-1797085-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
US-20060063805-A1 Thiazolinone 4-monosubstituted quinolines CHEN LI 2006-03-23 US disclosed
WO-2006029861-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063805-A1 Thiazolinone 4-monosubstituted quinolines CDK1, CDK14, CDK17 IDO1 2224/4885PDE4B 2268/4885PDE4D 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.